Lantern Pharma (LTRN) Q2 2024 earnings summary

Executive summary

• Advanced three active clinical trials and expanded AI-driven drug development collaborations, including a strategic partnership with Oregon Therapeutics for XCE853.

• Preliminary Phase 2 HARMONIC (LP-300) trial data showed an 86% clinical benefit rate and 43% objective response rate in the initial 7-patient cohort, with no dose-limiting toxicities.

• Advanced Phase 1 trials for LP-184 and LP-284, with no dose-limiting toxicities and over 40 patients dosed; preclinical data support synergy with PARP and checkpoint inhibitors.

• Starlight Therapeutics, a subsidiary, initiated site selection for Phase 1B/2 trials in recurrent GBM and received FDA Orphan Drug and Rare Pediatric Disease designations for STAR-001.

• Expanded global intellectual property portfolio, including a key Japanese patent for LP-284 targeting B-cell cancers.

Financial highlights

• Net loss for Q2 2024 was $4.96 million ($0.46/share), compared to $4.75 million ($0.44/share) in Q2 2023.

• R&D expenses rose to $3.9 million for Q2 2024, up from $3.6 million year-over-year, driven by increased clinical trial activity.

• General and administrative expenses decreased to $1.5 million for Q2 2024.

• Cash, cash equivalents, and marketable securities totaled $33.3 million as of June 30, 2024, down from $41.3 million at year-end 2023, providing runway into at least Q3 2025.

• Total assets were $35.6 million and total liabilities $4.7 million as of June 30, 2024.

Outlook and guidance

• Enrollment for LP-184 Phase 1a trial expected to complete in 2024, with initial safety and molecular data readout by year-end.

• LP-284 Phase 1a trial progressing, with potential advancement to Phase 1b/2 by late 2024 or early 2025.

• Starlight subsidiary advancing toward Phase 1b/2 trials in recurrent GBM; expansion of RADR AI platform and pursuit of additional collaborations.

• Cash position expected to support operations into at least Q3 2025; additional funding will be needed for future development.

• Plans to accelerate enrollment in the Harmonic trial at targeted sites in Asia.